These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34291090)

  • 21. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double Plant Homeodomain Fingers 2 (DPF2) Promotes the Immune Escape of Influenza Virus by Suppressing Beta Interferon Production.
    Shin D; Lee J; Park JH; Min JY
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28404846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Host immune response-inspired development of the influenza vaccine.
    Choi A; García-Sastre A; Schotsaert M
    Ann Allergy Asthma Immunol; 2020 Jul; 125(1):28-35. PubMed ID: 32325117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control.
    Bolton KJ; McCaw JM; Brown L; Jackson D; Kedzierska K; McVernon J
    PLoS One; 2015; 10(3):e0120138. PubMed ID: 25811654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.
    DeDiego ML; Anderson CS; Yang H; Holden-Wiltse J; Fitzgerald T; Treanor JJ; Topham DJ
    Immunology; 2016 Jun; 148(2):160-73. PubMed ID: 26854888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination strategies against influenza.
    Hanon E
    Bull Mem Acad R Med Belg; 2009; 164(10):283-7. PubMed ID: 20669618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
    Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating Influenza Infection, From Now and Into the Future.
    Davidson S
    Front Immunol; 2018; 9():1946. PubMed ID: 30250466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interplay of PA-X and NS1 Proteins in Replication and Pathogenesis of a Temperature-Sensitive 2009 Pandemic H1N1 Influenza A Virus.
    Nogales A; Rodriguez L; DeDiego ML; Topham DJ; Martínez-Sobrido L
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28637750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Annexins in Influenza Virus Replication and Pathogenesis.
    Ampomah PB; Kong WT; Zharkova O; Chua SCJH; Perumal Samy R; Lim LHK
    Front Pharmacol; 2018; 9():1282. PubMed ID: 30498445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response Modifiers: Tweaking the Immune Response Against Influenza A Virus.
    Elbahesh H; Gerlach T; Saletti G; Rimmelzwaan GF
    Front Immunol; 2019; 10():809. PubMed ID: 31031778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of reactive oxygen species production ameliorates inflammation induced by influenza A viruses via upregulation of SOCS1 and SOCS3.
    Ye S; Lowther S; Stambas J
    J Virol; 2015 Mar; 89(5):2672-83. PubMed ID: 25520513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influenza and Influenza Vaccine: A Review.
    Nypaver C; Dehlinger C; Carter C
    J Midwifery Womens Health; 2021 Jan; 66(1):45-53. PubMed ID: 33522695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Achieving clinical equality in an influenza pandemic: patent realities.
    Kane EM
    Seton Hall Law Rev; 2009; 39(4):1137-72. PubMed ID: 20718133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo.
    Khodamoradi S; Shenagari M; Kheiri MT; Sabahi F; Jamali A; Heidari A; Ashrafkhani B
    Arch Virol; 2018 Apr; 163(4):877-886. PubMed ID: 29270718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics.
    Vogel OA; Manicassamy B
    Front Microbiol; 2020; 11():135. PubMed ID: 32117155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.
    Ascough S; Paterson S; Chiu C
    Front Immunol; 2018; 9():323. PubMed ID: 29552008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sepsis Care Pathway 2019.
    Labib A
    Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
    [No Abstract]   [Full Text] [Related]  

  • 40. Current challenges: from the path of "original antigenic sin" towards the development of universal flu vaccines.
    Biswas A; Chakrabarti AK; Dutta S
    Int Rev Immunol; 2020; 39(1):21-36. PubMed ID: 31707873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.